HeartBeam Inc. (NASDAQ: BEAT) announced the pricing of its public offering of 12.5 million shares of common stock at $0.80 per share, generating gross proceeds of $10 million before fees and expenses.

The medical technology company granted underwriters a 30-day option to purchase up to 1.875 million additional shares to cover over-allotments at the same price. The offering is expected to close on or about April 16, 2026.

ClearCardio, described as HeartBeam's first commercial customer, is leading the offering alongside the company's executive leadership, board members, existing investors, and institutional investors. Titan Partners, a division of American Capital Partners, is serving as sole bookrunner.

HeartBeam plans to use proceeds to support commercialization of its FDA-cleared 12-lead synthesized ECG system, advance development of its extended-wear patch and heart attack detection initiatives, enhance AI capabilities, and for working capital and general corporate purposes.

"This financing provides us the capital to execute on our key strategic initiatives, as we expand the reach of our differentiated cardiac monitoring platform," said Robert Eno, Chief Executive Officer of HeartBeam.

The company develops cable-free devices that collect ECG signals in three dimensions and synthesize them into a 12-lead ECG. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025.

The offering is being conducted under a shelf registration statement filed with the Securities and Exchange Commission that became effective on March 17, 2026.